FOR IMMEDIATE RELEASE
- New product line is being made available in Latin America, the Middle East, Europe, and Southeast Asia, subject to applicable regulatory requirements
- MUSE cell introduction continues Cellgenic’s strategy of broadening its advanced cellular-technology portfolio
- Launch reflects continued international physician interest in emerging cellular science
MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the introduction of a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets, including Latin America, the Middle East, Europe, and Southeast Asia, subject to applicable local regulatory requirements.
MUSE cells are a class of pluripotent-like stem cells identified in adult tissue and studied for their stress-tolerance and multilineage differentiation properties. Cellgenic’s introduction of a MUSE cell line is intended to give physicians in its target markets access to an additional category of advanced cellular technology alongside its existing product offering.
The Company positioned the launch as part of a continued expansion of its cellular-technology portfolio, consistent with Cellgenic’s broader strategy of adding scientifically differentiated products for international physician networks.
“MUSE cell science has attracted significant attention across the regenerative medicine research community,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Bringing a MUSE cell product line to our international markets is consistent with how we’ve grown Cellgenic — one differentiated technology at a time, matched to real physician demand.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellgenic
Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com
